CTRI/2023/03/050333尚未招募4 期
A comparative, multicenter, prospective, randomized study to evaluate efficacy, safety and prevention of relapse with Elovera AD emollient vs plain emollient in mild to moderate atopic dermatitis
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients from 3 months-75 yrs. of age.
- •2. Patients who suffer from mild to moderate AD (IGA score of 2-3)
- •3. Patients willing to provide informed consent/parental consent/assent.
排除标准
- •1. Patients not deemed fit to be prescribed topical steroids
- •2. Patients not deemed to be fit to be prescribed emollients
- •3. Patients unwilling to give informed consent
研究者
相似试验
招募中
Unknown
A multicenter, prospective, comparative, randomized, independent rater-blind, superiority, pivotal clinical trial to compare the safety and efficacy of the Cognitive therapy software ‘SUPERBRAIN DEX’ for improving cognitive function with a control group for patients with mild cognitive impairmentMental and behavioural disordersKCT0009133Hanyang University Guri Hospital126
已完成
2 期
Clinical study on AP/VJT/SBO Ayurvedic Hair Oil in femalesCTRI/2022/05/042393AYURVED PRATISTHA
进行中（未招募）
3 期
A clinical research to study the safety, efficacy and immunogenicity of test pertuzumab in metastatic breast cancer patients.CTRI/2023/05/052997Enzene Biosciences Limited
已完成
3 期
Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)CTRI/2022/03/041271Zydus Research Centre Cadila Healthcare Limited268
已完成
3 期
Safety and efficacy Assessment of Trastuzumab emtansine of Cadila Healthcare Ltd in comparison with Reference drug(Trastuzumab emtansine) for the treatment of metastatic breast cancerCTRI/2018/07/014881Cadila Healthcare Ltd168